[1]李福明,夏 宇,魏 艳,等.晚期非小细胞肺癌初治患者的直接非医疗成本分析[J].卫生经济研究,2022,39(10):58-61.
　LI Fuming,XIA Yu,WEI Yan,et al.Analysis of Direct Non-medical Cost of Newly Treated Advanced Non-small Cell Lung Cancer Patients[J].Journal Press of Health Economics Research,2022,39(10):58-61.
点击复制

晚期非小细胞肺癌初治患者的直接非医疗成本分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年10期
页码:
58-61
栏目:
疾病经济负担
出版日期:
2022-09-26

文章信息/Info

Title:
Analysis of Direct Non-medical Cost of Newly Treated Advanced Non-small Cell Lung Cancer Patients
作者:
李福明1; 2; 夏 宇1; 2; 魏 艳1; 2; 陈英耀1; 2; 杨 毅1; 2
1.复旦大学公共卫生学院，上海 200032
2.国家卫生健康委员会卫生技术评估重点实验室（复旦大学）， 上海 200032
Author(s):
LI Fuming;  XIA Yu;  WEI Yan;  CHEN Yingyao;  YANG Yi
School of Public Health, Fudan University, Shanghai 200032, China
关键词:
晚期非小细胞肺癌; 直接非医疗成本; 疾病经济负担
Keywords:
advanced non-small cell lung cancer;  direct non-medical cost;  disease economic burden
分类号:
R195.4
文献标志码:
A
摘要:
目的：分析晚期非小细胞肺癌初治患者的直接非医疗成本及其影响因素，为相关部门提供对策建议。方法：对全国13家三级医疗机构中无EGFR/ALK突变的晚期NSCLC初治患者进行问卷调查，采用广义线性回归模型探索影响直接非医疗成本的相关因素。结果：晚期NSCLC初治患者平均病程6.5±8.4个月，直接非医疗成本9 667.52 元；综合医院就诊、病程越久、住院次数越多、每次住院天数越长的患者，直接非医疗成本越高。结论：我国晚期NSCLC初治患者直接非医疗负担较重，需要进一步采取有效措施减轻患者及其家庭的疾病经济负担，切实提高肿瘤医疗服务的可及性。
Abstract:
Objective To understand the direct non-medical cost of newly treated patients with advanced non-small cell lung cancer (NSCLC) and its influencing factors, so that this paper could provide countermeasures and suggestions for relevant departments. Methods A questionnaire survey was conducted among first-line/newly diagnosed NSCLC patients without EGFR/ALK mutations in 13 tertiary medical institutions in China, and generalized linear regression model (GLM) was used to explore the relevant factors affecting direct non-medical costs of this population. Results The average duration of newly treated NSCLC was 6.5±8.4 months, and the average direct non-medical cost was 9 667.52 yuan. Patients with visits in general hospitals, longer duration of disease, more times of hospitalization and more average days of hospitalization undertook more direct non-medical costs. Conclusion The direct non-medical burden of advanced NSCLC patients with first-line/newly diagnosed therapy is heavy. Further effective measures should be taken to reduce the economic burden of patients and their families, and improve the accessibility of cancer medical services.

参考文献/References:

[1] International agency for research on cancer.Global Cancer Observatory: Cancer Today[EB/OL].[2022-02-15].https://gco.iarc.fr/today.
[2] 胡毅，陶海涛. 晚期非小细胞肺癌的药物治疗进展[J].中国药物应用与监测，2014，11（6）：329-333.
[3] 曾理，蒋俊男，项莉.精准健康扶贫视角下农村大病患者直接非医疗负担分析[J].卫生经济研究，2019，36（6）：32-34.
[4] Bernard D S,Farr S L,Fang Z.National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer:2001 to 2008[J].J Clin Oncol,2011,29(20): 2821-2826.
[5] 王黔京.城乡居民大病保险受益群体与分配效应研究——基于贵州省的实地调查数据[J].现代预防医学，2021，48（22）：4117-4120.
[6] 王亭艳，曹凤，胡刚，等.新疆肺癌患者疾病经济负担及其影响因素分析[J].卫生软科学，2016，30（9）：17-20.
[7] Wood R,Taylor Stokes G.Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage[J].BMC Cancer, 2019,19(1):14.
[8] Jan S,Laba T L,Essue B M,et al.Action to address the household economic burden of non-communicable diseases[J].Lancet,2018,391(10134):2047-2058.

更新日期/Last Update: 2022-09-26